Theralase AGM Presentation Video
Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has released the video presentations conducted at the end of its Annual General and Special Meeting held on December 9, 2016 in Toronto, Canada.
The presentations were delivered by Dr. Lothar Lilge, Senior Scientist, Princess Margaret Cancer Center, University Health Network (“UHN”) and Dr. Girish Kulkarni, Uro-Oncologist, also from UHN.
In your next interview, I concur with the first poster.
-Have the other 2 patients received ‘Consent letters?’ and are enrolled?
-When is the post procedure follow up done for ‘safety/tox’ 1 month right whereby 3 month mark is efficacy signs.. please distinguish between the two?
Thanks
In your next interview with Roger, could you please have him explain when we will be getting information POST procedures for the first 3 patients. Will we hear information 30 days after the procedure or will the first we hear be 3 months after the procedures? And assuming not all 3 are done concurrently, will we hear only after a period when all 3 first patients have completed their procedures?